Product How it works Pricing Blog FAQ About Contact
United States

Damora Therapeutics (NASDAQ: DMRA) stock: the official figures

Damora Therapeutics (DAMORA THERAPEUTICS, INC.) is listed on Nasdaq under the ticker DMRA and belongs to the health care sector. In fiscal 2025 it reported a net loss of $209.8m, according to the annual accounts it filed with the regulator.

Identifiers for Damora Therapeutics: SEC CIK 1800315.

Fiscal 2025 figures

Consolidated annual accounts of Damora Therapeutics, in millions of US dollars
Item20252024Change
Operating profit−$210.9m−$22.3m—
Net profit−$209.8m−$21.4m—
Total assets$260.5m$17.1m+1,420.7%
Equity$240.4m$15.8m+1,418.4%
Cash$257.6m$14.2m+1,717.5%
Operating cash flow−$6.7m−$18.6m—

Margins are calculated from the filed figures: operating profit and net profit over revenue.

7 fiscal years

Net profit, in millions of US dollars-36.52019-34.82020-51.82021-61.62022-38.32023-21.42024-209.82025
Fiscal yearOperating profitNet profitEarnings per shareDocument
2025−$210.9m−$209.8m—Annual report
2024−$22.3m−$21.4m−$18.53Annual report
2023−$39.9m−$38.3m−$1.44Annual report
2022−$61.2m−$61.6m−$2.43Annual report
2021−$52.2m−$51.8m−$2.05Annual report
2020−$33.6m−$34.8m—Annual report
2019$39.0m−$36.5m—Annual report

The full income statement, balance sheet and cash flow statement are in the annual accounts of Damora Therapeutics. Purchases and sales by its executives and directors are in insider transactions.

Frequently asked questions about Damora Therapeutics

How much did Damora Therapeutics earn in fiscal 2025?
Damora Therapeutics reported a net loss of $209.8m for fiscal 2025. The year before it reported a net loss of $21.4m.
Where is Damora Therapeutics listed?
Damora Therapeutics is listed on Nasdaq under the ticker DMRA and belongs to the health care sector.
Where do the figures for Damora Therapeutics come from?
From the annual report (Form 10-K) that Damora Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

The annual accounts come from the annual report (Form 10-K) that Damora Therapeutics files with the SEC, the US securities regulator. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.